| 摘要 |
Use of gangliosides asialo-GM1 and/or GM1, or substances that simulate their carbohydrate component, as regards binding to specific antibodies, to produce an agent for binding or blocking antiasialo-GM1 and/or anti-GM1 antibodies (Ab) that bind to natural killer cells (NKC), for prevention, inhibition or treatment of malignant cancer. Independent claims are also included for the following: (1) similar use of the gangliosides for blocking antigen-presenting cells (APC) and/or for inducing T cell anergy; (2) use of the same gangliosides to prepare an affinity material for extracorporeal removal of Ab from the blood; and (3) composition for prevention or treatment of cancer that comprises, apart from a carrier, agents that bind to Ab so that binding of Ab to NKC is at least partly inhibited. |
